ArticleThe oncologist2026
Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS G12C mutations are rare in intrahepatic cholangiocarcinoma (iCCA), occurring in approximately 1% of cases. While adagrasib has shown efficacy in biliary tract cancers in clinical trials, real-world evidence for sotorasib remains limited. We report a 64-year-old male with advanced iCCA harboring a KRAS p.(G12C) mutation (58.07% allelic frequency) who progressed on multiple prior therapies including chemotherapy, immunotherapy, and targeted therapy. Disease progression was complicated by obstructive jaundice and the Eastern Cooperative Oncology Group (ECOG) performance status deterioration to 3, requiring percutaneous transhepatic cholangiodrainage (PTCD). Following initiation of sotorasib 480 mg daily, the patient achieved a marked partial radiographic response within 6 weeks. CA19-9 normalized, jaundice resolved, PTCD was removed, and performance status improved to ECOG 1. The patient received continuous sotorasib for 10 months, with the initial partial response lasting 8 months with no significant treatment-related adverse events. This case provides real-world evidence that sotorasib can induce durable responses in chemotherapy-refractory, KRAS G12C-mutant iCCA, including in patients with poor performance status and obstructive jaundice who would typically be excluded from clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.